SPATA2L

Across TCGA pan-cancer cohorts, SPATA2L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA2L data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SPATA2L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA2L expression acts as an unfavorable survival marker.

STAD, UCEC, and COAD are the cancer types where SPATA2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.192	0.537	.032	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.207	0.615	.018	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA2L–STAD (DFS)

Open the STAD breakdown →